Jazz Pharmaceuticals, a specialty pharmaceutical company focused on neurological and psychiatric drugs, announced the terms of its IPO Thursday. The company plans to offer 6 million shares and expects the price per share to be between $24.00 and $26.00. Morgan Stanley and Lehman Brothers are the bookrunners on the deal.
